SCHEMBL31701729

SCHEMBL31701729

O=S(=O)(Nc1ccc2ocnc2c1)c1ccccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTPN2 P17706 4/20 0.61
▸ PTPN1 P18031 4/20 0.61
▸ PTPN5 P54829 4/20 0.61
▸ NR1I2 O75469 4/20 0.53
▸ SLC22A12 Q96S37 2/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ PGR P06401 1/20 0.48
▸ PIK3CD O00329 1/20 0.47
▸ BRD4 O60885 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ PPARG P37231 1/20 0.45
▸ PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31700423 0.85 PTPN2 (0.61) PTPN2PTPN1PTPN5NR1I2MEN1
SCHEMBL31702050 0.85 PTPN1 (0.61) PTPN2PTPN1PTPN5MEN1KMT2A
SCHEMBL31702046 0.85 PTPN2 (0.61) PTPN2PTPN1PTPN5NR1I2SLC22A12
SCHEMBL31700420 0.85 PTPN1 (0.61) PTPN2PTPN1PTPN5NR1I2NPC1
SCHEMBL31700372 0.85 PTPN1 (0.61) PTPN2PTPN1PTPN5NPC1RAB9A
SCHEMBL31701128 0.81 PTPN2 (0.64) PTPN2PTPN1PTPN5SLC22A12KMT2A
SCHEMBL31700537 0.81 PTPN2 (0.63) PTPN2PTPN1PTPN5SLC22A12
SCHEMBL31700369 0.81 NPC1 (0.55) PTPN2PTPN1PTPN5NPC1RAB9A
SCHEMBL31700422 0.81 PTPN2 (0.63) PTPN2PTPN1PTPN5SLC22A12NPC1
SCHEMBL31701339 0.79 PTPN2 (0.59) PTPN2PTPN1PTPN5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319056-A1 METHODS FOR TREATING CANCER UNIV INDIANA TRUSTEES (US) 2025-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319056-A1 METHODS FOR TREATING CANCER HSP90AB1, HSP90B1, HSP90AB2P PTPN2 2771/4885PTPN1 3070/4885PTPN5 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback